TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000447510
  • Gene Name:CD133
  • mRNA database:Ensembl
  • mRNA expression :down-regulated
  • mRNA Method:RT-PCR
  • mRNA Pathway:AKT signaling pathways
  • Evidence:validated
  • (mRNA-drug)

Drug basic information

  • Drug ID:DB01169 (APRD00171)
  • Drug Name:Arsenic trioxide
  • Drug Method:down regulated the gene expression

Disease basic infommation

  • Disease:gallbladder carcinoma
  • Tissue:cell line (GBC)

Other information

  • Title:Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma
  • Journal:Cancer Lett
  • Published:2011
  • PubMed ID:21788103
  • Abstract:CD133+ tumor cells are responsible for the initiation, propagation and recurrence of tumors, which raises the question of how to effectively target CD133+ tumor cells. Arsenic trioxide (As2O3) has considerable efficacy in treating solid tumors with induction of apoptosis. Here, we found that purified CD133+ gallbladder carcinoma cells are highly resistant to conventional chemotherapy. However, As2O3 effectively induces CD133+ gallbladder carcinoma cells apoptosis. Treatment with As2O3 reduces CD133 expression at transcriptional levels. Furthermore, the ectopic expression of CD133 attenuated the apoptotic effect of As2O3 on cells through activation of AKT signaling pathways. Collectively, As2O3 effectively targets CD133 in gallbladder carcinoma, providing a new mechanism of As2O3-induced cell apoptosis and a better understanding of drug resistance in gallbladder carcinoma.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3